期刊文献+

Clinical Study on Treatment of Mid-Late Stage Gastric Carcinoma by Compound Xiansu Capsule (仙酥胶囊) Combined with Chemotherapy

Clinical Study on Treatment of Mid-Late Stage Gastric Carcinoma by Compound Xiansu Capsule (仙酥胶囊) Combined with Chemotherapy
原文传递
导出
摘要 Objective: To assess the effect and mechanism of compound Xiansu capsule (仙酥胶囊, XSC) combined with chemotherapy in treating gastric carcinoma of mid late stage. Methods: Sixty one patients of the test group were treated by XSC combined with chemotherapy and 30 patients of the control group treated with chemotherapy alone. The effect of treatment and cell mediated immunity of patients were observed. Results: The effective rate of the test group and the control group was 32.8% and 13.3% respectively ( P <0.05), the toxic reaction occurrence caused by chemotherapy was less in the former than that in the latter group ( P < 0.01). The CD 8 level of patients in the test group decreased, and CD 4/CD 8 level was raised obviously, which suggested that XSC had immuno regulating effect on T cell. Conclusion: XSC could enhance the efficacy and reduce the toxic and side effect of chemotherapy. To regulate the cell mediated immunity of patients is possibly its mechanism. Objective: To assess the effect and mechanism of compound Xiansu capsule (仙酥胶囊, XSC) combined with chemotherapy in treating gastric carcinoma of mid late stage. Methods: Sixty one patients of the test group were treated by XSC combined with chemotherapy and 30 patients of the control group treated with chemotherapy alone. The effect of treatment and cell mediated immunity of patients were observed. Results: The effective rate of the test group and the control group was 32.8% and 13.3% respectively ( P <0.05), the toxic reaction occurrence caused by chemotherapy was less in the former than that in the latter group ( P < 0.01). The CD 8 level of patients in the test group decreased, and CD 4/CD 8 level was raised obviously, which suggested that XSC had immuno regulating effect on T cell. Conclusion: XSC could enhance the efficacy and reduce the toxic and side effect of chemotherapy. To regulate the cell mediated immunity of patients is possibly its mechanism.
出处 《Chinese Journal of Integrative Medicine》 SCIE CAS 2001年第1期12-15,共4页 中国结合医学杂志(英文版)
关键词 compound Xiansu capsule CHEMOTHERAPY T lymphocyte subset gastric carcinoma compound Xiansu capsule, chemotherapy, T lymphocyte subset, gastric carcinoma
  • 相关文献

参考文献7

  • 1[1]National Tumor Prevention and Treatment Office, National Association of Anti-Cancer Co-edited. “Chinese common malignant tumor standard of diagnosis and treatment”, the fourth fascicle, 2nd edition. Beijing: Beijing Medical University and Chinese Union Medical University United Press, 1991∶14-50.
  • 2[2]SUN Y, ZHOU JC, chief edited. Clinical tumor medical handbook. 3rd edition. Beijing: People's Health Publishing House, 1996∶24.
  • 3[3]Jiangsu New Medical College, chief edited. Chinese drugs dictionary. Shanghai: Shanghai Science and Technology Press, 1986∶34.
  • 4[4]SHEN ZQ, SUN JX, HUANG LX. Astragalus in treating selective immunoglobin A deficiency. New Drug and Clinical 1997;16(4)∶246.
  • 5[5]DING HZ, YANG LY. Application of Ginseng Astragalus decoction in the hepatic artery ligation and embolization in treating mid-late stage liver cancer. CJITWM 1994;14(suppl)∶302.
  • 6[6]Berghella AM, Barni S, Robin T, et al. Progression mechanisms in gastric or colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumor stage correlation. Cancer Immunol 1994;38(3)∶160.
  • 7[7]Rosenberg SA, Kusugamik, Kawase T, et al. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1990;208∶121.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部